Foregut primary carcinomas - Revision history

Michael: /* IHC */

2025-08-29T14:51:56Z

IHC

← Older revision		Revision as of 14:51, 29 August 2025
Line 22:		Line 22:
	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:
	*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1.		*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1.
			*[[MMR]] (MLH1, MSH2, MSH6, PMS2).

			==Molecular==
			*FGFR2 mutation - seen in choleangiocarcinoma.<ref>{{cite journal \|authors=Vogel A, Segatto O, Stenzinger A, Saborowski A \|title=FGFR2 Inhibition in Cholangiocarcinoma \|journal=Annu Rev Med \|volume=74 \|issue= \|pages=293–306 \|date=January 2023 \|pmid=36170665 \|doi=10.1146/annurev-med-042921-024707 \|url=}}</ref>

	==See also==		==See also==

2021-08-03T15:28:10Z

IHC

← Older revision		Revision as of 15:28, 3 August 2021
Line 18:		Line 18:
	*CK20 -ve.		*CK20 -ve.
	*CDX2 -ve.		*CDX2 -ve.
	*[[HNF-1beta]] +ve (72-87% of cases +ve - in one study<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>).		*[[HNF-1beta]] +ve (72-87% of cases +ve in one study<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>).

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:

2021-08-03T15:28:02Z

IHC

← Older revision		Revision as of 15:28, 3 August 2021
Line 18:		Line 18:
	*CK20 -ve.		*CK20 -ve.
	*CDX2 -ve.		*CDX2 -ve.
	*[[HNF-1beta]] +ve.<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>		*[[HNF-1beta]] +ve (72-87% of cases +ve - in one study<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>).

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:

2021-08-03T15:25:59Z

IHC: +HNF1-beta

← Older revision		Revision as of 15:25, 3 August 2021
Line 18:		Line 18:
	*CK20 -ve.		*CK20 -ve.
	*CDX2 -ve.		*CDX2 -ve.
			*[[HNF-1beta]] +ve.<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:

2021-02-01T18:06:16Z

IHC

← Older revision		Revision as of 18:06, 1 February 2021
Line 20:		Line 20:

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:
	*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, TTF-1.		*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1.

	==See also==		==See also==

2021-01-28T19:46:23Z

IHC

← Older revision		Revision as of 19:46, 28 January 2021
Line 20:		Line 20:

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:
	*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, TTF-1.		*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, TTF-1.

	==See also==		==See also==

2021-01-28T19:45:02Z

IHC

← Older revision		Revision as of 19:45, 28 January 2021
Line 20:		Line 20:

	A (query) foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:
	*AE1/AE3, CK7, CK20, CK19, CDX2, CA-125~~, HepPar-1~~, GATA3, TTF-1.		*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, TTF-1.

	==See also==		==See also==

2021-01-28T19:44:21Z

IHC

← Older revision		Revision as of 19:44, 28 January 2021
Line 19:		Line 19:
	*CDX2 -ve.		*CDX2 -ve.

	A foregut primary panel for liver lesions:		A (query) foregut primary panel for liver lesions:
	*AE1/AE3, CK7, CK20, CK19, CDX2, CA-125, HepPar-1, GATA3, TTF-1.		*AE1/AE3, CK7, CK20, CK19, CDX2, CA-125, HepPar-1, GATA3, TTF-1.

2021-01-28T19:43:48Z

Foregut: +IHC

← Older revision		Revision as of 19:43, 28 January 2021
Line 12:		Line 12:
	*[[Pancreas]].<ref name=pmid23630303>{{cite journal \|authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA \|title=Development of the human pancreas from foregut to endocrine commitment \|journal=Diabetes \|volume=62 \|issue=10 \|pages=3514–22 \|date=October 2013 \|pmid=23630303 \|pmc=3781486 \|doi=10.2337/db12-1479 \|url=}}</ref>		*[[Pancreas]].<ref name=pmid23630303>{{cite journal \|authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA \|title=Development of the human pancreas from foregut to endocrine commitment \|journal=Diabetes \|volume=62 \|issue=10 \|pages=3514–22 \|date=October 2013 \|pmid=23630303 \|pmc=3781486 \|doi=10.2337/db12-1479 \|url=}}</ref>
	*Lower respiratory tract.		*Lower respiratory tract.

			==IHC==
			Foregut carcinomas are typically:
			*CK7 +ve.
			*CK20 -ve.
			*CDX2 -ve.

			A foregut primary panel for liver lesions:
			*AE1/AE3, CK7, CK20, CK19, CDX2, CA-125, HepPar-1, GATA3, TTF-1.

	==See also==		==See also==

2020-09-10T19:50:20Z

Foregut

← Older revision		Revision as of 19:50, 10 September 2020
Line 10:		Line 10:
	*[[Liver]].		*[[Liver]].
	*[[Gallbladder]].		*[[Gallbladder]].
	*[[Pancreas]].<ref name=pmid23630303>{{cite journal \|~~vauthors~~=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA \|title=Development of the human pancreas from foregut to endocrine commitment \|journal=Diabetes \|volume=62 \|issue=10 \|pages=3514–22 \|date=October 2013 \|pmid=23630303 \|pmc=3781486 \|doi=10.2337/db12-1479 \|url=}}</ref>		*[[Pancreas]].<ref name=pmid23630303>{{cite journal \|authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA \|title=Development of the human pancreas from foregut to endocrine commitment \|journal=Diabetes \|volume=62 \|issue=10 \|pages=3514–22 \|date=October 2013 \|pmid=23630303 \|pmc=3781486 \|doi=10.2337/db12-1479 \|url=}}</ref>
	*Lower respiratory tract.		*Lower respiratory tract.